Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL)

Next Previous
Trial Profile

A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lirilumab (Primary)
  • Indications Acute myeloid leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Ovarian cancer; Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
  • 13 May 2015 According to Innate Pharma media release, data from the trial will be presented at the ASCO (American Society of Clinical Oncology) annual meeting.
  • 17 Nov 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top